Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Filling a Transient Binding Pocket Reactivates Mutant Forms of the p53 Tumor Suppressor Protein

By LabMedica International staff writers
Posted on 20 Feb 2013
A computational method was used to match a transiently open pocket on the surface of a mutated form of the p53 tumor suppressor protein with a low molecular-weight drug that was able to fill the pocket and by doing so return the molecule to its active morphology.

The tumor suppressor p53 is the most frequently mutated gene in human cancer, and reactivation of mutant p53 by small molecules is an exciting potential cancer therapy. To this end investigators at the University of California, Irvine (USA) used an advanced computer program to screen a library of 2,298 small molecules for their potential to fill a binding pocket that is available about 5% of the time on the surface of the p53 protein between loop L1 and sheet S3 of the core domain. A paper published in the January 29, 2013, online edition of the journal Nature Communications explained that 45 of the most promising compounds were evaluated in biological assays. From these 45 compounds, only stictic acid fit into the protein pocket and reasserted the tumor-suppressing properties of the mutant p53 molecules.

Stictic acid is an aromatic organic compound that is a product of secondary metabolism in some species of lichens. It became the subject of cancer research after it was found that stictic acid extracted from Antarctic lichens had an apoptotic effect. In human osteosarcoma cells, stictic acid exhibited superior dose-dependent reactivation of p53 expression than did another reactivator, PRIMA-1.

“Stictic acid cannot be developed into a viable drug,” said contributing author Dr. Peter Kaiser, professor of biological chemistry at the University of California, Irvine. “Nonetheless, this work suggests that a comprehensive screening of small molecules with similar traits may uncover a usable compound that binds to this specific p53 pocket. The discovery and pharmaceutical development of such a compound could have a profound impact on cancer treatments. Instead of focusing on a specific form of the disease, oncologists could treat a wide spectrum of cancers, including those of the lung and breast. There is currently one group of experimental drugs - called Nutlins - that stop p53 degradation, but they do not target protein mutations as would a drug binding to the newly discovered pocket.”

Related Links:
University of California, Irvine



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.